CORRECTING AND REPLACING -- Bacterin Sets Annual Meeting and Record Dates
GlobeNewswire - Fri May 15, 3:00PM CDT
Bacterin International Holdings, Inc. (OTCQX:BONE), a leader in the development of revolutionary bone graft material, has established a record date for its 2015 annual meeting of stockholders.
Bacterin Internationals' (BONE) CEO Dan Goldberger on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed May 06, 12:57PM CDT
Bacterin International misses by $0.26, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue May 05, 3:57PM CDT
Bacterin Sets Annual Meeting and Record Dates
GlobeNewswire - Mon May 04, 8:03AM CDT
Bacterin International Holdings, Inc. (OTCQX:BONE), a leader in the development of revolutionary bone graft material, has established a record date for its 2015 annual meeting of stockholders.
Bacterin International Receives Coverage From Medicare Administrative Contractor (MAC) for hMatrix(R)
GlobeNewswire - Tue Apr 28, 6:30AM CDT
Bacterin International Holdings, Inc. (OTCQX:BONE), a leader in the development of revolutionary allograft, today announced that its Acellular Dermal Matrix allograft (ADM), hMatrix(R), has received coverage from Novitas Solutions, Inc. ("Novitas"
Bacterin to Report First Quarter 2015 Financial Results on May 5, 2015
GlobeNewswire - Thu Apr 23, 3:00PM CDT
Bacterin International Holdings, Inc. (OTCQX:BONE), a leader in the development of revolutionary bone graft material, today announced that it will release its financial results for the period ended March 31, 2015, on May 5, 2015 at the close of the financial markets.
Bacterin anticipates Q1 2015 revenue in higher USD9.4m - USD9.5m range
M2 - Fri Apr 10, 7:32AM CDT
Bone graft company Bacterin International Holdings (Other OTC:BONE) said on Thursday that it expects its total net revenue in the range of USD9.4m to USD9.5m in the Q1 2015.
Bacterin sees Q1 revenues of ~$9.5M
Seeking Alpha - at Seeking Alpha - Thu Apr 09, 10:21AM CDT
Bacterin Announces Preliminary First Quarter 2015 Results
GlobeNewswire - Thu Apr 09, 9:35AM CDT
Bacterin International Holdings, Inc. (OTCQX:BONE), a leader in the development of revolutionary bone graft material, today announced preliminary unaudited results for the first quarter of 2015.
Bacterin delisted from NYSE, trading commences on OTCQX
Seeking Alpha - at Seeking Alpha - Thu Apr 09, 8:38AM CDT
OTC Markets Group Welcomes Bacterin International Holdings to OTCQX®
PR Newswire - Thu Apr 09, 8:06AM CDT
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced Bacterin International Holdings, Inc. (OTCQX: BONE), a leader in the development of revolutionary bone graft material, has qualified to trade on OTCQX®, the best marketplace for established, global and growth companies. Bacterin previously traded on the NYSE MKT exchange.
Bacterin International to list its common stock on OTCQX Marketplace
M2 - Thu Apr 09, 6:18AM CDT
Biologics products company Bacterin International Holdings (NYSE MKT:BONE) stated on Wednesday that the trading its common stock on the NYSE MKT will be suspended following NYSE Regulation's suspension notice.
Bacterin International to Begin Trading on OTCQX Marketplace
GlobeNewswire - Wed Apr 08, 7:42PM CDT
Bacterin International Holdings, Inc. (NYSE MKT:BONE), a leader in the development of revolutionary bone graft material, today announced that it received written notice from the staff at NYSE Regulation, Inc. that trading in the company's common stock will be suspended on the NYSE MKT, and the company's common stock will begin trading on the OTCQX(R) marketplace. The suspension notice follows the company's previously announced appeal of NYSE Regulation's delisting determination. Investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
Bacterin awarded OsteoSponge technology patent in the US
M2 - Tue Apr 07, 6:52AM CDT
Bone graft company Bacterin International Holdings (NYSE MKT:BONE) reported on Monday the receipt of the US Patent No. 8,992,964 entitled "Process for Demineralization of Bone Matrix with Preservation of Natural Growth Factors" from the United States Patent and Trademark Office.
Bacterin awarded patent covering component in OsteoSponge
Seeking Alpha - at Seeking Alpha - Mon Apr 06, 9:16AM CDT
Bacterin Announces OsteoSponge(R) Patent
GlobeNewswire - Mon Apr 06, 6:30AM CDT
Bacterin International Holdings, Inc. (NYSE MKT:BONE), a leader in the development of revolutionary bone grafts, is pleased to announce that the United States Patent and Trademark Office has issued US Patent No. 8,992,964 entitled "Process for Demineralization of Bone Matrix with Preservation of Natural Growth Factors." The issued claims in the patent cover certain demineralized bone matrixes containing minimum levels of bone morphogenetic protein-2 (BMP-2), which include products in Bacterin's OsteoSponge product line. Bacterin has pending continuing applications in the United States to pursue protection on other aspects of its bone demineralization technology.
Bacterin International net loss improves in Q4 and FY14
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 7:26AM CDT
Bacterin's full-year guidance exceeds analyst estimates
Seeking Alpha - at Seeking Alpha - Tue Mar 17, 3:44PM CDT